Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy

The impact of cumulative dosing and premature drug discontinuation (PMDD) of bortezomib (V), thalidomide (T), and dexamethasone (D) on overall survival (OS), event-free survival (EFS), time to next therapy, and post-relapse survival in Total Therapy 3 were examined, using time-dependent methodology,...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: van Rhee, Frits, Szymonifka, Jackie, Anaissie, Elias, Nair, Bijay, Waheed, Sarah, Alsayed, Yazan, Petty, Nathan, Shaughnessy, John D., Hoering, Antje, Crowley, John, Barlogie, Bart
Format: Artigo
Langue:Inglês
Publié: American Society of Hematology 2010
Sujets:
Clinical Trials and Observations
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC2938233/
https://ncbi.nlm.nih.gov/pubmed/20501894
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2010-01-264333
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires